RESUMO
UFT-E granules were administered as postoperative adjuvant chemotherapy to patients who had undergone surgery for gastric cancer, colorectal cancer or breast cancer. After treatment for one year, the dose conditions were investigated. The subjects were patients under 75 years of age in whom malignant tumors had been confirmed histologically, who had undergone curative resections, had no marked complications, and from whom personal informed consent had been obtained. As a rule, UFT-E granules were administered orally 450 mg (t.i.d.)/day continuously for one year beginning two weeks after surgery. The dose rate was studied from patient records and the tegafur blood concentrations on the 1st, 2nd, 6th, 8th and 12th month. The appearance of complications or clinical lab test abnormalities was also checked. A total of 19 cases were compliant among the 5 gastric cancer, 10 colorectal cancer, and 7 breast cancer patients. The mean administration period was 459 days (29-879 days), and the mean completion rate was 92.5%. The complications in 4 cases (21.1%) were relatively mild. A comparison of the prescribed dosage and patient records revealed a mean dose rate of 86.3%. From these findings, long-term administration of UFT-E granules with mild side effects is considered feasible. However, to achieve high compliance, it is considered necessary to gain a clear picture of dose conditions from patients records and other sources.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Administração Oral , Adulto , Idoso , Neoplasias da Mama/cirurgia , Quimioterapia Adjuvante , Neoplasias Colorretais/cirurgia , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Cooperação do Paciente , Neoplasias Gástricas/cirurgia , Tegafur/administração & dosagem , Uracila/administração & dosagemRESUMO
BACKGROUND: Bile cytology from percutaneous transhepatic cholangio-drainage (PTCD) is a useful procedure in case of obstructive jaundice. CASE: Repeated cytology via PTCD from a cystically dilated duct in a 56-year-old female with a long clinical history permitted a diagnosis of squamous cell carcinoma (SCC). The smears showed excessive benign-appearing squamous cells with or without a nucleus and a few keratinized- and nonkeratinized-type SCC cells. No adenocarcinoma-derived cells were identified. No focus of SCC was detected clinically. The resected hepatic specimen disclosed a keratinized-type SCC simultaneous with benign metaplastic squamous epithelium. CONCLUSION: This case of cytology of primary SCC of the liver seems to be the first reported. Even when showing a great number of benign-appearing squamous cells, the possibility of malignancy should not be ruled out. Repeating the cytology from PTCD is effective for a diagnosis.
Assuntos
Carcinoma de Células Escamosas/patologia , Neoplasias Hepáticas/patologia , Carcinoma de Células Escamosas/complicações , Colestase Intra-Hepática/complicações , Colestase Intra-Hepática/patologia , Colestase Intra-Hepática/fisiopatologia , Drenagem , Feminino , Humanos , Fígado/patologia , Fígado/cirurgia , Neoplasias Hepáticas/complicações , Pessoa de Meia-Idade , Tomógrafos ComputadorizadosRESUMO
The lymphocyte subsets and IL-2R (p55/Tac) in breast cancer patients were analyzed using monoclonal antibody and flow cytometry until 6 post-operative month. Results were as follows: 1. Lymphocyte fraction of CD3, 4, 8 was maintained from pre-operative to post-operative 6 month. 2. IL-2R value was lower in recurrence group than in breast benign disease group and it was lower. In pre-operative IL-2R in Stage III group than in Stage I and, Stage II. It was lower in DNA aneuploidy group than in DNA diploidy group. 3. At the post-operative 6 month, IL-2R was higher in Stage III group, ly-factor positive group, v-factor positive group and DNA aneuploidy group than in recurrence group. When breast cancer recurred after resection, IL-2R value returned to initial value. In conclusion, IL-2R may be possibly one of the factors of recurrence of breast cancer.
Assuntos
Neoplasias da Mama/diagnóstico , Subpopulações de Linfócitos , Receptores de Interleucina-2/análise , Adulto , Idoso , Neoplasias da Mama/cirurgia , Complexo CD3/análise , Linfócitos T CD4-Positivos , Antígenos CD8/análise , Feminino , Humanos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , PrognósticoAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Tamoxifeno/uso terapêutico , Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Mitomicina , Mitomicinas/administração & dosagem , Indução de Remissão , Tegafur/administração & dosagem , Uracila/administração & dosagemRESUMO
We studied the effect of Cepharanthin on bone marrow suppression induced by adjuvant chemotherapy in primary breast cancer patients in our hospital. The 36 patients with breast cancer were divided into two groups. Both groups were administered of MMC 20 mg intravenously on the day of radical operation. One group (23 patients) was administered of Cepharanthin 60 mg every day, but the other (13 patients) group was not administered. In the leukocyte count at 3 weeks after post operation, 82.6% (19 out of 23) of the patients who were administered cepharanthin kept more than 70% of pre-operation's leukocyte. On the other hand, only 46.1% (6 out of 13) of the patients who were not administered Cepharanthin kept more than 70% of pre-operation's leukocyte. The number of thrombocyte was not decreased in both groups. Side effects by Cepharanthin were not observed in this study.
